期刊
CURRENT OPINION IN PHARMACOLOGY
卷 11, 期 5, 页码 433-438出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2011.07.008
关键词
-
New resistance challenges continue to evolve and spread worldwide. In an otherwise mature field, antibacterial drug development is primarily driven by resistance trends with a focus on development of new analogs of known scaffolds to strengthen them against class-specific resistance mechanisms. Currently new analogs of cephalosporins (with or without beta-lactamase inhibitors), oxazolidinones, glycopeptides, quinolones, aminoglycosides, tetracyclines, and ketolides are in clinical studies. While showing some benefit, these new analogs only partially address the clinical crisis of multidrug-resistant pathogens; this is especially the case for Gram-negative bacteria. The medical community faces grim reality - general solutions to the treatment of rapidly spreading multidrug-resistant bacteria are neither on the horizon nor anticipated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据